Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

48.06USD
9:36pm IST
Change (% chg)

$0.27 (+0.56%)
Prev Close
$47.79
Open
$48.08
Day's High
$48.23
Day's Low
$47.72
Volume
422,150
Avg. Vol
4,525,834
52-wk High
$63.69
52-wk Low
$44.30

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Announces Dividend
Friday, 14 Jun 2019 

June 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND.BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY ONE CENTS PER SHARE.  Full Article

Bristol-Myers Squibb Says Elkins Will Receive A Cash Sign-On Payment Of $2.1 Mln
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB - ELKINS WILL RECEIVE A CASH SIGN-ON PAYMENT OF $2.1 MILLION.BRISTOL-MYERS SQUIBB CO - WITH APPOINTMENT AS EVP AND CFO, ELKINS WILL RECEIVE AN ANNUAL BASE SALARY OF $1 MILLION.BRISTOL-MYERS SQUIBB CO - ELKINS WILL ALSO BE ELIGIBILE FOR A GRANT OF LONG-TERM INCENTIVE AWARDS IN 2020 VALUED AT $4.8 MILLION.  Full Article

Bristol-Myers Says David Elkins Will Be Appointed Co's Executive Vice President & CFO
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES POST-CLOSING LEADERSHIP TEAM.BRISTOL-MYERS SQUIBB CO - SAMIT HIRAWAT WILL JOIN BRISTOL-MYERS SQUIBB AS CHIEF MEDICAL OFFICER, GLOBAL DRUG DEVELOPMENT.BRISTOL-MYERS SQUIBB CO - DAVID ELKINS WILL BE APPOINTED COMPANY'S EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.BRISTOL-MYERS SQUIBB CO - RUPERT VESSEY , WILL SERVE AS PRESIDENT, RESEARCH & EARLY DEVELOPMENT.BRISTOL-MYERS SQUIBB CO - CAFORIO WILL CONTINUE TO SERVE AS CHAIRMAN OF BOARD AND CHIEF EXECUTIVE OFFICER OF COMPANY.BRISTOL-MYERS SQUIBB CO - DAVID ELKINS IS CURRENTLY CHIEF FINANCIAL OFFICER OF CELGENE.BRISTOL-MYERS - FOLLOWING DEAL CLOSE, CHARLES BANCROFT TO WORK WITH ELKINS TO ENSURE AN EFFECTIVE TRANSITION OF ALL FINANCIAL AND OPERATIONAL MATTERS.BRISTOL-MYERS SQUIBB CO - CHRIS BOERNER WILL CONTINUE IN HIS ROLE AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIALIZATION OFFICER.  Full Article

Heat Biologics Provides Data From Phase 2 Study Investigating Hs-110 In Combination With BMY's Nivolumab
Monday, 3 Jun 2019 

June 3 (Reuters) - Heat Biologics Inc ::HEAT BIOLOGICS - PROVIDES DATA FROM ONGOING PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BMY'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB.HEAT BIOLOGICS INC - UPDATED RESULTS WERE OBTAINED FROM COHORT B PATIENTS WHOSE DATA HAS MATURED AN ADDITIONAL 3 MONTHS SINCE LAST REPORTED.HEAT BIOLOGICS INC - ANNOUNCES DATA SUGGESTING THAT HS-110 PLUS NIVOLUMAB MAY RESTORE CLINICAL BENEFIT AFTER CHECKPOINT INHIBITOR TREATMENT FAILURE.HEAT BIOLOGICS INC - CLINICAL BENEFIT OBSERVED IN 55% OF PATIENTS RECEIVING HS-110 PLUS NIVOLUMAB AFTER CHECKPOINT INHIBITOR TREATMENT FAILURE.HEAT BIOLOGICS - HS-110 IN COMBINATION WITH NIVOLUMAB DEMONSTRATES CLINICAL ACTIVITY IN LOW CD8+ TIL 'COLD TUMOR' PATIENTS AND PD-L1 NEGATIVE TUMORS.HEAT BIOLOGICS INC - OCCURRENCE OF DERMAL INJECTION SITE REACTIONS IS ASSOCIATED WITH IMPROVED PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL.HEAT BIOLOGICS INC - TREATMENT WITH HS-110 IN COMBINATION WITH NIVOLUMAB WAS WELL TOLERATED.  Full Article

Bristol-Myers Squibb Says Phase 3 Checkmate -498 Study Did Not Meet Primary Endpoint
Thursday, 9 May 2019 

May 9 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES PHASE 3 CHECKMATE -498 STUDY DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL WITH OPDIVO (NIVOLUMAB) PLUS RADIATION IN PATIENTS WITH NEWLY DIAGNOSED MGMT-UNMETHYLATED GLIOBLASTOMA MULTIFORME.BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF OPDIVO WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES IN SOLID TUMORS.BRISTOL-MYERS SQUIBB CO - WILL COMPLETE A FULL EVALUATION OF DATA FROM CHECKMATE -498 AND WORK WITH INVESTIGATORS.  Full Article

Bristol-Myers Squibb Says Requisite Number Of Consents Received To Adopt Proposed Amendments With Respect To All Outstanding Notes Of Celgene Corporation
Thursday, 2 May 2019 

May 1 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES RESULTS OF EARLY PARTICIPATION IN EXCHANGE OFFERS AND CONSENT SOLICITATIONS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS SQUIBB - REQUISITE NUMBER OF CONSENTS RECEIVED TO ADOPT PROPOSED AMENDMENTS WITH RESPECT TO ALL OUTSTANDING NOTES OF CELGENE CORPORATION.  Full Article

Celgene Q1 Earnings Per Share $2.14
Friday, 26 Apr 2019 

April 25 (Reuters) - Celgene Corp ::CELGENE REPORTS FIRST QUARTER 2019 OPERATING AND FINANCIAL RESULTS.Q1 REVENUE $4.025 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.01 BILLION.Q1 EARNINGS PER SHARE $2.14.Q1 EARNINGS PER SHARE ESTIMATE $2.43 -- REFINITIV IBES DATA.REAFFIRMING 2019 GUIDANCE AND 2020 FINANCIAL TARGETS.REVLIMID SALES FOR Q1 WERE $2,577 MILLION, AN INCREASE OF 15 PERCENT YEAR-OVER-YEAR.OTEZLA SALES FOR Q1 WERE $389 MILLION, A 10 PERCENT INCREASE YEAR-OVER-YEAR.ACQUISITION BY BRISTOL-MYERS SQUIBB EXPECTED TO CLOSE IN Q3 OF 2019.QTRLY ADJUSTED. EARNINGS PER SHARE $2.55.FY2019 EARNINGS PER SHARE VIEW $10.70, REVENUE VIEW $17.11 BILLION -- REFINITIV IBES DATA.  Full Article

Bristol-Myers CFO Says Will Focus On Smaller Deals In The Near Term
Thursday, 25 Apr 2019 

April 25 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB CFO SAYS OPDIVO IS THE LEADING IMMUNONCOLOGY AGENT IN SECOND LINE LUNG CANCER, BUT SIZE OF ELIGIBLE POPULATION IS FALLING.BRISTOL-MYERS SQUIBB CFO SAYS WILL FOCUS ON SMALLER AND EARLIER STAGE DEALS IN THE NEAR TERM : CONF. CALL.  Full Article

Bristol-Myers Squibb Reports First Quarter Financial Results
Thursday, 25 Apr 2019 

April 25 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB REPORTS FIRST QUARTER FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.10.Q1 GAAP EARNINGS PER SHARE $1.04.Q1 REVENUE $5.9 BILLION VERSUS REFINITIV IBES ESTIMATE OF $5.75 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.09 -- REFINITIV IBES DATA.RAISES FY 2019 NON-GAAP EARNINGS PER SHARE VIEW TO $4.10 TO $4.20.RAISES FY 2019 GAAP EARNINGS PER SHARE VIEW TO $3.84 TO $3.94.REAFFIRMS NON-GAAP EPS GUIDANCE RANGE OF $4.10-$4.20.QTRLY U.S. REVENUES INCREASED 24% TO $3.4 BILLION IN QUARTER COMPARED TO SAME PERIOD A YEAR AGO.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $10.0 BILLION, WITH A NET CASH POSITION OF $4.0 BILLION, AS OF MARCH 31, 2019.RESULTS FOR Q1 OF 2019 INCLUDE $187 MILLION OF CELGENE-RELATED ACQUISITION AND INTEGRATION EXPENSES.COMPANY TODAY ANNOUNCED TOPLINE RESULTS FROM PHASE 2 CHECKMATE -714 TRIAL EVALUATING OPDIVO VERSUS OPDIVO PLUS YERVOY.STUDY DID NOT MEET ITS PRIMARY ENDPOINTS.QTRLY OPDIVO WORLWIDE REVENUE $1,801 MILLION VERSUS $1,511 MILLION.SEES 2019 WORLDWIDE REVENUES INCREASING IN MID-SINGLE DIGITS.QTRLY ELIQUIS WORLDWIDE REVENUE $1,925 MILLION VERSUS $1,506 MILLION.SEES 2019 GROSS MARGIN AS A PERCENTAGE OF REVENUE TO BE APPROXIMATELY 70% FOR BOTH GAAP AND NON-GAAP.QTRLY SPRYCEL WORLDWIDE REVENUE $459 MILLION VERSUS $438 MILLION.BRISTOL-MYERS SQUIBB - SALE OF UPSA CONSUMER HEALTH BUSINESS TO TAISHO PHARMACEUTICAL FOR $1.6 BILLION IS ANTICIPATED TO BE COMPLETED IN JULY 2019.  Full Article

Famewave Announces Clinical Collaboration With Bristol Myers Squibb For The Planned Phase 1/2 Trial In Non-Small Cell Lung Cancer
Friday, 12 Apr 2019 

April 12 (Reuters) - :FAMEWAVE ANNOUNCES CLINICAL COLLABORATION WITH BRISTOL MYERS SQUIBB FOR THE PLANNED PHASE 1/2 TRIAL IN NON-SMALL CELL LUNG CANCER TO EVALUATE IMMUNO-ONCOLOGY CANDIDATE CM-24 IN COMBINATION WITH NIVOLUMAB (OPDIVO®).FAMEWAVE LTD - WILL FUND AND SPONSOR STUDY AND BRISTOL MYERS SQUIBB WILL SUPPLY NIVOLUMAB.  Full Article

Photo

Investor Ackman opposes United Technologies' aerospace merger with Raytheon - source

Billionaire investor William Ackman's activist hedge fund Pershing Square Capital Management LP is opposing United Technologies Corp's planned $120 billion aerospace merger with defence contractor Raytheon Co, a person familiar with the matter said on Tuesday.